Mycobacterium tuberculosis H37Rv: In Silico Drug Targets Identification by Metabolic Pathways Analysis
- PMID: 24719775
- PMCID: PMC3955624
- DOI: 10.1155/2014/284170
Mycobacterium tuberculosis H37Rv: In Silico Drug Targets Identification by Metabolic Pathways Analysis
Abstract
Mycobacterium tuberculosis (Mtb) is a pathogenic bacteria species in the genus Mycobacterium and the causative agent of most cases of tuberculosis. Tuberculosis (TB) is the leading cause of death in the world from a bacterial infectious disease. This antibiotic resistance strain lead to development of the new antibiotics or drug molecules which can kill or suppress the growth of Mycobacterium tuberculosis. We have performed an in silico comparative analysis of metabolic pathways of the host Homo sapiens and the pathogen Mycobacterium tuberculosis (H37Rv). Novel efforts in developing drugs that target the intracellular metabolism of M. tuberculosis often focus on metabolic pathways that are specific to M. tuberculosis. We have identified five unique pathways for Mycobacterium tuberculosis having a number of 60 enzymes, which are nonhomologous to Homo sapiens protein sequences, and among them there were 55 enzymes, which are nonhomologous to Homo sapiens protein sequences. These enzymes were also found to be essential for survival of the Mycobacterium tuberculosis according to the DEG database. Further, the functional analysis using Uniprot showed involvement of all the unique enzymes in the different cellular components.
Similar articles
-
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915. Curr Pharm Des. 2014. PMID: 24245755
-
Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis.Comput Biol Chem. 2005 Oct;29(5):368-78. doi: 10.1016/j.compbiolchem.2005.07.001. Epub 2005 Oct 6. Comput Biol Chem. 2005. PMID: 16213791
-
Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.Comput Biol Chem. 2019 Apr;79:91-102. doi: 10.1016/j.compbiolchem.2019.01.011. Epub 2019 Jan 24. Comput Biol Chem. 2019. PMID: 30743161
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy.Metabolites. 2021 Feb 2;11(2):88. doi: 10.3390/metabo11020088. Metabolites. 2021. PMID: 33540752 Free PMC article. Review.
Cited by
-
Comparative Genome and Network Centrality Analysis to Identify Drug Targets of Mycobacterium tuberculosis H37Rv.Biomed Res Int. 2015;2015:212061. doi: 10.1155/2015/212061. Epub 2015 Nov 5. Biomed Res Int. 2015. PMID: 26618166 Free PMC article.
-
Maximum flow approach to prioritize potential drug targets of Mycobacterium tuberculosis H37Rv from protein-protein interaction network.Clin Transl Med. 2015 Dec;4(1):61. doi: 10.1186/s40169-015-0061-6. Epub 2015 Jun 5. Clin Transl Med. 2015. PMID: 26061871 Free PMC article.
-
Early Drug Development and Evaluation of Putative Antitubercular Compounds in the -Omics Era.Front Microbiol. 2021 Feb 2;11:618168. doi: 10.3389/fmicb.2020.618168. eCollection 2020. Front Microbiol. 2021. PMID: 33603720 Free PMC article. Review.
-
Ample glycosylation in membrane and cell envelope proteins may explain the phenotypic diversity and virulence in the Mycobacterium tuberculosis complex.Sci Rep. 2019 Feb 27;9(1):2927. doi: 10.1038/s41598-019-39654-9. Sci Rep. 2019. PMID: 30814666 Free PMC article.
-
Subtractive Genomics Approach for Identification of Novel Therapeutic Drug Targets in Mycoplasma genitalium.Pathogens. 2021 Jul 21;10(8):921. doi: 10.3390/pathogens10080921. Pathogens. 2021. PMID: 34451385 Free PMC article.
References
-
- Kaufmann SHE. Envisioning future strategies for vaccination against tuberculosis. Nature Reviews Immunology. 2006;6(9):699–704. - PubMed
-
- Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nature Reviews Immunology. 2005;5(10):819–826. - PubMed
-
- Dutta A, Singh SK, Ghosh P, Mukherjee R, Mitter S, Bandyopadhyay D. In silico identification of potential therapeutic targets in the human pathogen Helicobacter pylori . In Silico Biology. 2006;6(1-2):43–47. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources